Elinogrel: pharmacological principles, preclinical and early phase clinical testing

Papers of special note have been highlighted as: ▪ of interest ▪▪ of considerable interest

Bibliography

• 1  Angiolillo DJ, Ueno M, Goto S: Basic principles of platelet biology and clinical implications. Circ. J.74(4),597–607 (2010).
  Medline CASGoogle Scholar
• 2  Born GV: Adenosine diphosphate as a mediator of platelet aggregation in vivo: an editorial view. Circulation72(4),741–746 (1985).
  Medline CASGoogle Scholar
• 3  Hechler B, Cattaneo M, Gachet C: The P2 receptors in platelet function. Semin. Thromb. Haemost.31(2),150–161 (2005).
  Medline CASGoogle Scholar
• 4  Gachet C: Regulation of platelet functions by P2 receptors. Annu. Rev. Pharmacol. Toxicol.46,277–300 (2006).
  Medline CASGoogle Scholar
• 5  Conley PB, Delaney SM: Scientific and therapeutic insights into the role of the platelet P2Y₁₂ receptor in thrombosis. Curr. Opin. Hematol.10(5),333–338 (2003).
  Medline CASGoogle Scholar
• 6  Rolf MG, Mahaut-Smith MP: Effects of enhanced P2X₁ receptor Ca²⁺ influx on functional responses in human platelets. Thromb. Haemost.88(3),495–502 (2002).
  Medline CASGoogle Scholar
• 7  Bertrand ME, Rupprecht HJ, Urban P, Gershlick AH; CLASSICS Investigators: Double-blind study of the safety of clopidogrel with and without a loading dose in combination with aspirin compared with ticlopidine in combination with aspirin after coronary stenting: the clopidogrel aspirin stent international cooperative study (CLASSICS). Circulation102(6),624–629 (2000).
  Medline CASGoogle Scholar
• 8  Cadroy Y, Bossavy JP, Thalamas C, Sagnard L, Sakariassen K, Boneu B: Early potent antithrombotic effect with combined aspirin and a loading dose of clopidogrel on experimental arterial thrombogenesis in humans. Circulation101(24),2823–2828 (2000).
  Medline CASGoogle Scholar
• 9  Yusuf S, Zhao F, Mehta SR et al.: Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N. Engl. J. Med.345(7),494–502 (2001).
  Medline CASGoogle Scholar
• 10  Chen ZM, Jiang LX, Chen YP et al.: Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet366(9497),1607–1621 (2005).
  Medline CASGoogle Scholar
• 11  Sabatine MS, Cannon CP, Gibson CM et al.: Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. N. Engl. J. Med.352(12),1179–1189 (2005).
  Medline CASGoogle Scholar
• 12  Mehta SR, Yusuf S, Peters RJ et al.: Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet358(9281),527–533 (2001).
  Medline CASGoogle Scholar
• 13  Steinhubl SR, Berger PB, Mann JT 3rd et al.: Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA288(19),2411–2420 (2002).
  Medline CASGoogle Scholar
• 14  Angiolillo DJ, Fernandez-Ortiz A, Bernardo E et al.: Variability in individual responsiveness to clopidogrel: clinical implications, management, and future perspectives. J. Am. Coll. Cardiol.49(14),1505–1516 (2007).
  Medline CASGoogle Scholar
• 15  Ferreiro JL, Angiolillo DJ: Clopidogrel response variability: current status and future directions. Thromb. Haemost.102(1),7–14 (2009).
  Medline CASGoogle Scholar
• 16  Angiolillo DJ, Ferreiro JL: Platelet adenosine diphosphate P2Y₁₂ receptor antagonism: benefits and limitations of current treatment strategies and future directions. Rev. Esp. Cardiol.63(1),60–76 (2010).
  MedlineGoogle Scholar
• 17  Jernberg T, Payne CD, Winters KJ et al.: Prasugrel achieves greater inhibition of platelet aggregation and a lower rate of non-responders compared with clopidogrel in aspirin-treated patients with stable coronary artery disease. Eur. Heart J.27(15),1166–1173 (2006).
  Medline CASGoogle Scholar
• 18  Wiviott SD, Trenk D, Frelinger AL et al.: Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: the Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation – Thrombolysis in Myocardial Infarction 44 trial. Circulation116(25),2923–2932 (2007).
  Medline CASGoogle Scholar
• 19  Capranzano P, Ferreiro JL, Angiolillo DJ: Prasugrel in acute coronary syndrome patients undergoing percutaneous coronary intervention. Expert Rev. Cardiovasc. Ther.7(4),361–369 (2009).
  Medline CASGoogle Scholar
• 20  Wiviott SD, Braunwald E, McCabe CH et al.; for the TRITON-TIMI 38 Investigators: Prasugrel versus clopidogrel in patients with acute coronary syndromes. N. Engl. J. Med.357(20),2015–2021 (2007).
  Google Scholar
• 21  Kushner FG, Hand M, Smith SC et al.: Updates: ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction (updating the 2004 guideline and 2007 focused update) and ACC/AHA/SCAI guidelines on percutaneous coronary intervention (updating the 2005 guideline and 2007 focused update). J. Am. Coll. Cardiol.54(23),2205–2241 (2009).
  MedlineGoogle Scholar
• 22  Capodanno D, Dharmashankar K, Angiolillo DJ: Mechanism of action and clinical development of ticagrelor, a novel platelet ADP P2Y₁₂ receptor antagonist. Expert Rev. Cardiovasc. Ther.8(2),151–158 (2010).
  Medline CASGoogle Scholar
• 23  Wallentin L, Becker RC, Budaj A et al.: Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N. Engl. J. Med.361(11),1045–1057 (2009).
  Medline CASGoogle Scholar
• 24  Ferreiro JL, Ueno M, Angiolillo DJ: Cangrelor: a review on its mechanism of action and clinical development. Expert Rev. Cardiovasc. Ther.7(10),1195–1201 (2009).
  Medline CASGoogle Scholar
• 25  Harrington RA, Stone GW, McNulty S et al.: Platelet inhibition with cangrelor in patients undergoing PCI. N. Engl. J. Med.361(24),2318–2329 (2009).
  Medline CASGoogle Scholar
• 26  Bhatt DL, Lincoff M, Gibson M et al.: Intravenous platelet blockade with cangrelor during PCI. N. Engl. J. Med.361(24),2330–2341 (2009).
  Medline CASGoogle Scholar
• 27  Oestreich JH: Elinogrel, a reversible P2Y₁₂ receptor antagonist for the treatment of acute coronary syndrome and prevention of secondary thrombotic events. Curr. Opin. Investig. Drugs11(3),340–348 (2010).
  Medline CASGoogle Scholar
• 28  Steinhubl SR, Oh JJ, Oestreich JH, Ferraris S, Charnigo R, Akers WS: Transitioning patients from cangrelor to clopidogrel: pharmacodynamic evidence of a competitive effect. Thromb. Res.121(4),527–534 (2008).
  Medline CASGoogle Scholar
• 29  Dovlatova NL, Jakubowski JA, Sugidachi A Heptinstall S: The reversible P2Y antagonist cangrelor influences the ability of the active metabolites of clopidogrel and prasugrel to produce irreversible inhibition of platelet function. J. Thromb. Haemost.6(7),1153–1159 (2008).
  Medline CASGoogle Scholar
• 30  Stephens G, Gao D, Phillips DR, Andre P: Differential effects of anti-platelet drugs on thrombus formation and stability. J. Thromb. Haemost.5(Suppl. 2), Abstract O-W-034 (2007).
  MedlineGoogle Scholar
• 31  Conley P, Jurek M, Stephens G et al.: A novel pharmacodynamic perfusion chamber assay reveals superior and unique antithrombotic activities of a direct-acting P2Y₁₂ antagonist, PRT128, relative to clopidogrel. Blood108(11), Abstract 900 (2006).
  Google Scholar
• 32  Angiolillo DJ, Shoemaker SB, Desai B et al.: Randomized comparison of a high clopidogrel maintenance dose in patients with diabetes mellitus and coronary artery disease: results of the Optimizing Antiplatelet Therapy in Diabetes Mellitus (OPTIMUS) study. Circulation115(6),708–716 (2007).
  Medline CASGoogle Scholar
• 33  Haberstock-Debic H, Andre P, Delaney SM et al.: A functional pool of P2Y₁₂ receptors exposed upon platelet activation persists in mice treated with high dose clopidogrel, and can be blocked by elinogrel, a direct acting, reversible P2Y₁₂ inhibitor Thromb. Haemost.7(Suppl. 2), Abstract PP-MO-045 (2009).
  Google Scholar
• 34  Haberstock-Debic H, Andre P, Delaney S et al.: The clopidogrel-insensitive pool of P2Y₁₂ receptors exposed upon platelet activation contributes to thrombus formation and can be blocked by elinogrel, a direct acting, reversible P2Y₁₂ inhibitor. Eur. Heart J.30(Suppl.), Abstract 884 (2009).▪ Preclinical study demonstrating that elinogrel achieves greater inhibition of thrombotic activity than clopidogrel.
  Google Scholar
• 35  Andre P, Conley PB, Deguzman F et al.: Combination of direct acting FXa inhibitor and P2Y₁₂ antagonist at non-effective doses provides significant inhibition of arterial thrombosis. Circulation118(Suppl.), Abstract 1718 (2008).
  Google Scholar
• 36  Andre P, DeGuzman F, Mills S et al.: Clopidogrel and prasugrel prolong primary hemostasis in the mouse beyond levels associated with P2Y₁₂ inhibition. J. Thromb. Haemost.7(Suppl. 2), Abstract AS-TH-022 (2009).▪ Preclinical study demonstrating that elinogrel is associated with a low volume of blood loss compared with clopidogrel and prasugrel.
  Google Scholar
• 37  Desai M, Gretler D, Gu Z-M et al.: Metabolism and excretion of PRT060128, a new direct-acting, reversible P2Y₁₂ inhibitor, in healthy human subjects. Ann. Meet. Exposition Am. Assoc. Pharm. Scientists Abstract T3312 (2008).
  Google Scholar
• 38  Lieu HD, Conley PB, Andre P et al.: Initial intravenous experience with PRT060128 (PRT128), an orally-available, direct-acting, and reversible P2Y₁₂ inhibitor. J. Thromb. Haemost.5(Suppl. 2), Abstract P-T-292 (2007).▪ Phase I study evaluating the tolerability and pharmacokinetic and pharmocodynamic parameters of elinogrel administered as a single intravenous bolus.
  Google Scholar
• 39  Gretle DD, Conley PB, Andre P et al.: ‘First in human’ experience with PRT060128, a new direct-acting, reversible, P2Y₁₂ inhibitor for IV and oral use. J. Am. Coll. Cardiol.49(Suppl. 9), Abstract 1002–1128 (2007).
  Google Scholar
• 40  Gurbel PA, Bliden KP, Antonino MJ et al.: The effect of elinogrel on high platelet reactivity during dual antiplatelet therapy and the relation to CYP 2C19*2 genotype: first experience in patients. J. Thromb. Haemost.8(1),43–53 (2009).▪▪ Phase I study demonstrating that hyper-platelet reactivity accompanying standard maintenance clopidogrel and aspirin therapy is reversibly overcome by a single 60 mg oral dose of elinogrel.
  MedlineGoogle Scholar
• 41  Conley PB, Andre P, Stephens G et al.: ADP-mediated aggregation as a pharmacodynamic assay underestimates the antithrombotic activity of elinogrel, a competitive, reversible P2Y₁₂ inhibitor, relative to clopidogrel. J. Thromb. Haemost.7, Suppl 2, Abstract PP-TH-027 (2009).
  Google Scholar
• 42  Folie BJ, McIntire LV: Mathematical analysis of mural thrombogenesis. Concentration profiles of platelet-activating agents and effects of viscous shear flow. Biophys. J.56(6),1121–1141 (1989).
  Medline CASGoogle Scholar
• 43  Marín F, González-Conejero R, Capranzano P, Bass TA, Roldán V, Angiolillo DJ: Pharmacogenetics in cardiovascular antithrombotic therapy. J. Am. Coll. Cardiol.54(12),1041–1057 (2009).
  Medline CASGoogle Scholar
• 44  Berger JS, Roe MT, Gibson CM et al.: Safety and feasibility of adjunctive antiplatelet therapy with intravenous elinogrel, a direct-acting and reversible P2Y₁₂ ADP-receptor antagonist, before primary percutaneous intervention in patients with ST-elevation myocardial infarction: the Early Rapid Reversal of Platelet Thrombosis with Intravenous Elinogrel Before PCI to Optimize Reperfusion in Acute Myocardial Infarction (ERASE MI) pilot trial. Am. Heart J.158(6),998.E1–1004.E1 (2009).▪▪ Phase II study evaluating the safety and tolerability of escalating doses (10, 20, 40 and 60 mg) of elinogrel administered as a single intravenous bolus.
  Google Scholar